MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
AFYA stock logo

AFYA

Afya Limited

$14.96
-0.01
 (-0.07%)
Exchange:  NASDAQ
Market Cap:  1.354B
Shares Outstanding:  87.683M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Consumer Defensive
Industry:  Education & Training Services
   
CEO:  Virgilio Deloy Capobianco Gibbon
Full Time Employees:  5260
Address: 
Alameda Oscar Niemeyer, No. 119
Nova Lima
MG
BR
Website:  https://www.afya.com.br
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/10 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue2,875,9133,304,3293,624,629.082
Gross Profit1,766,1002,088,7262,336,543.183
EBITDA1,105,3891,218,0231,189,373.769
Operating Income767,0611,012,1131,189,373.769
Net Income386,324631,510737,680.255

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets7,584,4818,829,5399,353,237.741
Total Liabilities3,941,4694,518,9564,464,507.370
Total Stockholders Equity3,601,5054,269,9554,849,361.136
Total Debt2,675,3443,173,4973,118,447.223
Cash and Cash Equivalents553,030911,0151,124,816.227

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow1,043,6231,432,6591,199,238.119
Capital Expenditure-245,428-136,924-162,752.949
Free Cash Flow798,1951,295,7351,036,485.170
Net Income429,582631,510737,680.255
Net Change in Cash-540,052357,985317,151.890

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2028Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)4,654,003.254Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)4,817,625.808Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)4,711,830.649Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)1,704,203.280Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)1,764,118.600Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)1,725,378.520Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)1,126,728.788Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)1,138,088.868Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)1,132,408.828Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)1,579,750.656Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,635,290.548Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,599,379.534Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)12.410Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)12.470Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)12.350Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
612.94M  ?P/S
 (TTM)
: 
1.93
?Net Income
 (TTM)
: 
117.143M  ?P/E
 (TTM)
: 
9.45
?Enterprise Value
 (TTM)
: 
9.145B  ?EV/FCF
 (TTM)
: 
7.92
?Dividend Yield
 (TTM)
: 
0.04  ?Payout Ratio
 (TTM)
: 
0.02
?ROE
 (TTM)
: 
0.16  ?ROIC
 (TTM)
: 
0.13
?Net Debt
 (TTM)
: 
366.225M  ?Debt/Equity
 (TTM)
: 
0.64
?P/B
 (TTM)
: 
1.47  ?Current Ratio
 (TTM)
: 
2.2

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
7.34Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates AFYA intrinsic value between $76.29 – $209.16 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate AFYA Intrinsic Value

Common questions about AFYA valuation

Is Afya Limited (AFYA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Afya Limited (AFYA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is AFYA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AFYA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is AFYA’s P/E ratio?

You can see AFYA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for AFYA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is AFYA a good long-term investment?

Whether AFYA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

AFYA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.07
MARKETSnap

Trading Metrics:

Open: 14.88   Previous Close: 14.97
Day Low: 14.79   Day High: 15.26
Year Low: 13   Year High: 19.9
Price Avg 50: 14.47   Price Avg 200: 14.99
Volume: 114063   Average Volume: 107175

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

AFYA vs. LOPE: Which Stock Is the Better Value Option?
16-03-2026 12:40
AFYA vs. LOPE: Which Stock Is the Better Value Option?
AFYA or LOPE: Which Is the Better Value Stock Right Now?
01-04-2026 12:41
AFYA or LOPE: Which Is the Better Value Stock Right Now?
Surging Earnings Estimates Signal Upside for Afya (AFYA) Stock
20-03-2026 13:21
Surging Earnings Estimates Signal Upside for Afya (AFYA) Stock
Afya Limited (NASDAQ:AFYA) Sees Significant Growth in Short Interest
17-03-2026 02:28
Afya Limited (NASDAQ:AFYA) Sees Significant Growth in Short Interest
Afya Limited Announces Fourth Quarter and Twelve Months 2025 Financial Results
12-03-2026 20:21
Afya Limited Announces Fourth Quarter and Twelve Months 2025 Financial Results
Afya Limited Announces Dividend Distribution of R$307.4 Million
12-03-2026 17:10
Afya Limited Announces Dividend Distribution of R$307.4 Million

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read